At a glance
ClinicalIndex Comparison RecordN/AActive· 814 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx)
In Brief
An observational study for Non-small Cell Lung Cancer. Active but no longer recruiting, targeting 814 participants across 18 sites.
Detailed Summary
To study the NSCLC evolutionary genomic landscape between primary and metastatic sites and the dynamics of intratumour heterogeneity over time combined with detailed clinical, histopathological and cancer phenotypic annotation for each patient, in order to significantly improve the outcomes of NSCLC patients (e.g. reduce their chance of recurrence and improve survival).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesUnited Kingdom
CollaboratorsCancer Research UK
Timeline
N/AActive
201320142015201620172018201920202021202220232024202520262027202820292030203120322033203420352036
First PostedJun 2013
Enrollment StartApr 2014
TodayJul 2026
Primary CompletionNov 2035
First PostedJun 28, 2013
Enrollment StartApr 1, 2014
Primary CompletionNov 1, 2035
TodayJul 2, 2026
Enrollment to primary: 21.6 yearsPosted 13.0 years agoPrimary completion in 9.3 years